» Articles » PMID: 34968288

Epigenomic Remodeling in Huntington's Disease-Master or Servant?

Overview
Journal Epigenomes
Date 2021 Dec 30
PMID 34968288
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In light of our aging population, neurodegenerative disorders are becoming a tremendous challenge, that modern societies have to face. They represent incurable, progressive conditions with diverse and complex pathological features, followed by catastrophic occurrences of massive neuronal loss at the later stages of the diseases. Some of these disorders, like Huntington's disease (HD), rely on defined genetic factors. HD, as an incurable, fatal hereditary neurodegenerative disorder characterized by its mid-life onset, is caused by the expansion of CAG trinucleotide repeats coding for glutamine (Q) in exon 1 of the huntingtin gene. Apart from the genetic defect, environmental factors are thought to influence the risk, onset and progression of HD. As epigenetic mechanisms are known to readily respond to environmental stimuli, they are proposed to play a key role in HD pathogenesis. Indeed, dynamic epigenomic remodeling is observed in HD patients and in brains of HD animal models. Epigenetic signatures, such as DNA methylation, histone variants and modifications, are known to influence gene expression and to orchestrate various aspects of neuronal physiology. Hence, deciphering their implication in HD pathogenesis might open up new paths for novel therapeutic concepts, which are discussed in this review.

Citing Articles

The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

Bora Yildiz C, Du J, Mohan K, Zimmer-Bensch G, Abdolahi S Epigenomics. 2025; 17(2):125-140.

PMID: 39829063 PMC: 11792803. DOI: 10.1080/17501911.2024.2442297.


Histone post-translational modification and heterochromatin alterations in neurodegeneration: revealing novel disease pathways and potential therapeutics.

Fisher R, Torrente M Front Mol Neurosci. 2024; 17:1456052.

PMID: 39346681 PMC: 11427407. DOI: 10.3389/fnmol.2024.1456052.


Neuroinflammation and the role of epigenetic-based therapies for Huntington's disease management: the new paradigm.

Temgire P, Arthur R, Kumar P Inflammopharmacology. 2024; 32(3):1791-1804.

PMID: 38653938 DOI: 10.1007/s10787-024-01477-0.


Role of DNMTs in the Brain.

Bora Yildiz C, Zimmer-Bensch G Adv Exp Med Biol. 2022; 1389:363-394.

PMID: 36350518 DOI: 10.1007/978-3-031-11454-0_15.


The emerging role of long non-coding RNAs, microRNAs, and an accelerated epigenetic age in Huntington's disease.

Ghafouri-Fard S, Khoshbakht T, Hussen B, Taheri M, Ebrahimzadeh K, Noroozi R Front Aging Neurosci. 2022; 14:987174.

PMID: 36185471 PMC: 9520620. DOI: 10.3389/fnagi.2022.987174.


References
1.
Wei C, Luo T, Zou S, Wu A . The Role of Long Noncoding RNAs in Central Nervous System and Neurodegenerative Diseases. Front Behav Neurosci. 2018; 12:175. PMC: 6172704. DOI: 10.3389/fnbeh.2018.00175. View

2.
Lunkes A, Lindenberg K, Ben-Haiem L, Weber C, Devys D, Landwehrmeyer G . Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell. 2002; 10(2):259-69. DOI: 10.1016/s1097-2765(02)00602-0. View

3.
Kaas G, Zhong C, Eason D, Ross D, Vachhani R, Ming G . TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. Neuron. 2013; 79(6):1086-93. PMC: 3816951. DOI: 10.1016/j.neuron.2013.08.032. View

4.
Morfini G, Pigino G, Brady S . Polyglutamine expansion diseases: failing to deliver. Trends Mol Med. 2005; 11(2):64-70. DOI: 10.1016/j.molmed.2004.12.002. View

5.
Maunakea A, Chepelev I, Cui K, Zhao K . Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 2013; 23(11):1256-69. PMC: 3817542. DOI: 10.1038/cr.2013.110. View